1. Home
  2. CTS vs NRIX Comparison

CTS vs NRIX Comparison

Compare CTS & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CTS Corporation

CTS

CTS Corporation

HOLD

Current Price

$52.37

Market Cap

1.6B

Sector

Technology

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$15.86

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTS
NRIX
Founded
1896
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
CTS
NRIX
Price
$52.37
$15.86
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
$29.46
AVG Volume (30 Days)
180.3K
786.8K
Earning Date
05-13-2026
05-01-2026
Dividend Yield
0.30%
N/A
EPS Growth
15.87
N/A
EPS
2.19
N/A
Revenue
$541,318,000.00
$76,987,000.00
Revenue This Year
$5.55
N/A
Revenue Next Year
$5.00
$29.30
P/E Ratio
$24.37
N/A
Revenue Growth
4.95
99.31
52 Week Low
$34.02
$8.18
52 Week High
$59.66
$22.50

Technical Indicators

Market Signals
Indicator
CTS
NRIX
Relative Strength Index (RSI) 48.59 43.15
Support Level $40.41 $15.22
Resistance Level $59.66 $19.98
Average True Range (ATR) 1.76 0.71
MACD -0.67 0.06
Stochastic Oscillator 9.27 36.57

Price Performance

Historical Comparison
CTS
NRIX

About CTS CTS Corporation

CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEM) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China; Singapore; the Czech Republic; Taiwan, Denmark, and other countries.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: